Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.
Voisin M, de Medina P, Mallinger A, Dalenc F, Huc-Claustre E, Leignadier J, Serhan N, Soules R, Ségala G, Mougel A, Noguer E, Mhamdi L, Bacquié E, Iuliano L, Zerbinati C, Lacroix-Triki M, Chaltiel L, Filleron T, Cavaillès V, Al Saati T, Rochaix P, Duprez-Paumier R, Franchet C, Ligat L, Lopez F, Record M, Poirot M, Silvente-Poirot S. Voisin M, et al. Among authors: dalenc f. Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9346-E9355. doi: 10.1073/pnas.1707965114. Epub 2017 Oct 12. Proc Natl Acad Sci U S A. 2017. PMID: 29078321 Free PMC article.
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.
Dalenc F, Doisneau-Sixou SF, Allal BC, Marsili S, Lauwers-Cances V, Chaoui K, Schiltz O, Monsarrat B, Filleron T, Renée N, Malissein E, Meunier E, Favre G, Roché H. Dalenc F, et al. Clin Cancer Res. 2010 Feb 15;16(4):1264-71. doi: 10.1158/1078-0432.CCR-09-1192. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145184 Clinical Trial.
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.
Zindy P, Bergé Y, Allal B, Filleron T, Pierredon S, Cammas A, Beck S, Mhamdi L, Fan L, Favre G, Delord JP, Roché H, Dalenc F, Lacroix-Triki M, Vagner S. Zindy P, et al. Among authors: dalenc f. Cancer Res. 2011 Jun 15;71(12):4068-73. doi: 10.1158/0008-5472.CAN-11-0420. Epub 2011 Apr 15. Cancer Res. 2011. PMID: 21498638
[Neoadjuvant treatment of breast cancer: implications for the pathologist].
Le Guellec S, Perallon R, Alunni JP, Charitansky H, Leaha C, Gonzalez AM, Chateau MC, Simony-Lafontaine J, Jacot W, Gutowski M, Penault-Llorca F, Dalenc F, Lacroix-Triki M. Le Guellec S, et al. Among authors: dalenc f. Ann Pathol. 2011 Dec;31(6):442-54. doi: 10.1016/j.annpat.2011.10.003. Epub 2011 Nov 23. Ann Pathol. 2011. PMID: 22172117 Review. French.
214 results